Aarey Drugs

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE198H01019
  • NSEID: AAREYDRUGS
  • BSEID: 524412
INR
115.75
4.1 (3.67%)
BSENSE

Nov 20

BSE+NSE Vol: 2.68 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Albert David
Medicamen Biotec
Aarey Drugs
Lyka Labs
Jenburkt Pharma
Ambalal Sarabhai
Zenotech Lab.
Astonea Labs
Ennature Bio Pha
Accretion Nutrav
Sat Kartar Life
Why is Aarey Drugs & Pharmaceuticals Ltd ?
1
Weak Long Term Fundamental Strength with a -18.37% CAGR growth in Operating Profits over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 1.28
  • The company has been able to generate a Return on Equity (avg) of 3.75% signifying low profitability per unit of shareholders funds
2
Flat results in Sep 26
  • NET SALES(Latest six months) At Rs 133.25 cr has Grown at -28.50%
  • NON-OPERATING INCOME(Q) is 97.59 % of Profit Before Tax (PBT)
3
Stock is technically in a Bullish range
  • The technical trend has improved from Mildly Bullish on 18-Nov-26 and has generated 7.57% returns since then
  • Multiple factors for the stock are Bullish like MACD, Bollinger Band, KST and OBV
4
With ROCE of 2.2, it has a Fair valuation with a 2.1 Enterprise value to Capital Employed
  • The stock is trading at a discount compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 24.99%, its profits have risen by 26.3% ; the PEG ratio of the company is 6.6
stock-recommendationReal-Time Research Report
Verdict Report
How much should you hold?
  1. Overall Portfolio exposure to Aarey Drugs should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Aarey Drugs for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Aarey Drugs
24.99%
0.47
53.29%
Sensex
-2.0%
-0.13
14.98%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
-3.08%
EBIT Growth (5y)
-18.37%
EBIT to Interest (avg)
1.28
Debt to EBITDA (avg)
7.16
Net Debt to Equity (avg)
0.32
Sales to Capital Employed (avg)
2.81
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
5.72%
ROCE (avg)
2.55%
ROE (avg)
3.75%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
82
Industry P/E
19
Price to Book Value
2.46
EV to EBIT
148.22
EV to EBITDA
66.45
EV to Capital Employed
2.10
EV to Sales
1.00
PEG Ratio
6.64
Dividend Yield
NA
ROCE (Latest)
2.17%
ROE (Latest)
3.00%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company
PAT(9M)

Higher at Rs 3.95 Cr

-3What is not working for the Company
NET SALES(Latest six months)

At Rs 133.25 cr has Grown at -28.50%

NON-OPERATING INCOME(Q)

is 97.59 % of Profit Before Tax (PBT

Loading Valuation Snapshot...
Here's what is working for Aarey Drugs
Profit After Tax (PAT) - Nine Monthly
At Rs 3.95 cr has Grown at 38.11%
Year on Year (YoY)
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Profit After Tax (PAT) - Nine Monthly
Higher at Rs 3.95 Cr
than preceding 12 month period ended Sep 2026 of Rs 3.43 cr
MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months

PAT (Rs Cr)

Here's what is not working for Aarey Drugs
Net Sales - Latest six months
At Rs 133.25 cr has Grown at -28.50%
Year on Year (YoY)
MOJO Watch
Near term sales trend is negative

Net Sales (Rs Cr)

Non Operating Income - Quarterly
is 97.59 % of Profit Before Tax (PBT)
MOJO Watch
The company's income from non business activities is high; which is not a sustainable business model

Non Operating Income to PBT